You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Controlled and extended release metoprolol reduced death, hospital admissions, and symptoms in chronic heart failure

https://doi.org/10.1136/ebm.5.5.142

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2000) JAMA 283, 1295. Hjalmarson A, Goldstein S, Fagerberg B, et al. , for the MERIT-HF Study Group.. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF).. Mar 8;. :. –1302.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients with symptomatic chronic heart failure, do controlled and extended release metoprolol succinate (a β-blocker) reduce mortality, hospital admissions, and symptoms?

    Design

    Randomised (allocation concealed*), blinded (outcome assessor, {patients, and clinicians}†),* placebo controlled trial with a mean follow up of 1 year.

    Setting

    313 investigational sites in the US and 13 European countries.

    Patients

    3991 patients (mean age 64 y, 78% men) who had had symptomatic heart failure (New York Heart Association [NYHA] class II to IV) for ≥3 months, a decreased ejection fraction (≤ 0.40), and a resting heart rate ≥68 beats/minute and had received optimal treatment for ≥2 weeks before randomisation. Exclusion criteria included acute myocardial infarction or unstable angina pectoris ≤ 28 …

    View Full Text

    Footnotes

    • Source of funding: AstraZeneca.

    • For correspondence: Dr B Fagerberg, Wallenberg Laboratory for Cardiovascular Research, Sahlgren-ska University Hospital, SE-413 45 Gothenburg, Sweden. Fax +46 31 885747.

    • ↵* See glossary.

    • ↵† Information provided by authors.